Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00418886
Status:
COMPLETED
Last Update Posted:
2023-09-28
First Post:
2007-01-04
Brief Title:
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
A Phase III Randomized Double-blinded Parallel Group Multi-centre Study to Assess the Efficacy and Safety of ZD6474 ZACTIMA in Combination With Pemetrexed Alimta Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC
Status:
COMPLETED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ZEAL
Brief Summary:
Non-small cell lung cancer NSCLC can be treated with drugs that kill tumour cells stop them from dividing or stop the growth of the blood supply that cancers need to grow and spread Clinical research has shown that drugs that inhibit vascular endothelial growth factor receptor VEGFR or epidermal growth factor receptor EGFR signalling can increase overall survival in patients with advanced non-small cell lung cancer NSCLC Preclinical studies have shown that vandetanib ZD6474 is an inhibitor of both VEGFR and EGFR signalling Giving vandetanib may therefore inhibit the growth of cancer cells by blocking their blood supply and by stopping them from dividing This lung cancer study is to investigate if adding vandetanib to Alimta pemetrexed is more effective than Alimta pemetrexed alone
Detailed Description:
This randomized phase III non-small cell lung cancer clinical trial is studying the effect of Alimta pemetrexed plus vandetanib to see how well the combination works compared to Alimta pemetrexed alone in patients who have previously been treated for non-small cell lung cancer NSCLC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LPS15296 | OTHER | Sanofi | None |
| EUDRACT No 2006-003695-35 | None | None | None |